Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacyclics’ Ibrutinib Scoops Another FDA Breakthrough Designation, And Pfizer Joins The Club

Executive Summary

Pharmacyclics and partner J&J announce a third breakthrough therapy designation from FDA for ibrutinib for hard-to-treat CLL patients with the 17p deletion. Also, NIH investigators report positive Phase II data confirming single-agent activity at the AACR meeting in Washington, D.C.

You may also be interested in...



Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals

Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.

Ibrutinib’s Clean Label For Mantle Cell Leukemia Bodes Well For CLL Claim

Pharmacyclics/Janssen’s Imbruvica carries a high list price, but also patient support.

J&J Highlights Late-Stage R&D Prospects Across Pharma Division

J&J says its success at integrating external and internal innovation, focus on understanding causes of disease and commercial excellence have helped its pharma subsidiary weather a $9 billion patent cliff and recoup growth prospects. One observation from its May 23 analyst meeting: seemingly more than most companies, Janssen systemically incorporates biomarkers and companion diagnostics beyond oncology into all of its core development programs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel